21:15 中概股盘前表现活跃，迅雷大涨超23%，爱奇艺涨17%，斗鱼涨超9%。 21:30 美股开盘丨美股三大指数小幅低开中概股普涨 道指跌0.14%，标普500指数跌0.09%，纳指跌0.06%。中概股普涨，纳斯达克中国金龙指数涨1.2%，迅 雷涨超21%，爱奇艺涨超16%。诺和诺德涨超5%，其新药获批后降低Ozempic价格。 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 道琼斯工业指数 | 44883.39 | -62.73 | -0.14% | | 纳斯达克指数 | 21609.23 c | -13.75 | -0.06% | | 标普500 | 6443.85 | -5.95 | -0.09% | 16:34 联合健康美股盘前涨超3%。 （文章来源：第一财经） 21:06 诺和诺德美股盘前涨超5%，美国FDA批准将减肥药Wegovy用于肝病治疗。 ...

每经AI快讯，8月18日，美股三大指数开盘集体下跌，道琼斯指数跌0.14%，标普500指数跌0.11%，纳 斯达克综合指数跌0.05%。中概股普涨，迅雷涨超21%，爱奇艺涨超16%。诺和诺德涨超5%。 ...

Novo Nordisk is slashing the cost of Ozempic for cash-paying patients after the diabetes shot became the poster child for high US drug prices. https://t.co/4oygIL7lub ...

Novo Nordisk's cash-pay offering will expand access to eligible Type 2 diabetes patients who don't have insurance coverage for the weekly injection. In March, the company began to offer Wegovy for half its list price to cash-paying Americans. Patients can pay $499 in cash per month for three dose sizes of Ozempic. They can get the price through platforms including the drug's official website, Novo Nordisk's patient assistance program and the company's recently launched direct-to-consumer online pharmacy, th ...

CONTACT: CONTACT US HERE: DEADLINE: September 30, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form-3/? id=161651&from=4 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NVO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. ...

Group 1 - Ukrainian President Zelensky is set to meet with US President Trump on August 18, 2023, to discuss the ongoing Russia-Ukraine conflict, followed by a multilateral meeting with European leaders [1] - Major US stock indices, including Dow Jones, S&P 500, and Nasdaq, experienced slight declines, with Dow futures down 0.15%, S&P 500 futures down 0.16%, and Nasdaq futures down 0.16% [2] - Semiconductor stocks in the US saw a collective decline, with Intel down 1.18%, AMD down 0.77%, and Nvidia down 0.38% [3] Group 2 - The Federal Reserve has relaxed its regulatory stance on banks' cryptocurrency activities, leading to a drop in cryptocurrency exchange stocks, with Coinbase down 1.67% and Circle down 1.07% [5] - Novo Nordisk's weight loss drug Wegovy received FDA approval for treating metabolic fatty liver disease, resulting in a 4.02% increase in the company's stock [6] - OpenAI employees plan to sell approximately $6 billion worth of stock at a valuation of $500 billion to a group of investors including Thrive Capital and SoftBank [7] Group 3 - Tesla is offering rental discounts of about 40% in the UK due to declining sales, with July sales dropping to 987 units, a year-on-year decrease of approximately 60% [8] - NIO announced plans to enter the markets of Singapore, Uzbekistan, and Costa Rica between 2025 and 2026, with a collaboration in Singapore to launch a right-hand drive model [9]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S on behalf of investors who acquired the company's securities between May 7, 2025, and July 28, 2025, alleging misrepresentations regarding the growth potential of its diabetes/obesity drug, GLP-1 [1][3]. Group 1 - The lawsuit claims that the defendants made misrepresentations about Novo's growth potential related to its diabetes/obesity drug, GLP-1 [3]. - The deadline for potential lead plaintiffs to file papers is September 30, 2025 [4]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5].

Core Viewpoint - Novo Nordisk's stock price has significantly declined, leading to an attractive valuation with a price-to-earnings ratio below its long-term average, despite a downward revision in 2025 earnings expectations and slowing growth. The core products Ozempic and Wegovy continue to show strong sales performance and global expansion potential, making it a "strong buy" for long-term investors [2][7]. Valuation Context - The company has increased capital expenditures significantly, approximately four times previous levels, which has compressed free cash flow in the short term. This investment is primarily directed towards production facilities rather than technology sectors, similar to trends seen in tech giants like Meta and Amazon [3]. Product Demand and Supply Issues - There is a warning that the shortage of Ozempic will persist until the fourth quarter, particularly in the EU, while the U.S. market has sufficient supply. This shortage reflects high market demand, and if production can be accelerated, revenue growth potential could be substantial. Capital expenditures are expected to remain high in the coming years, potentially reaching double-digit percentages of sales [5][6]. Earnings Guidance Adjustment - The management has revised the 2025 fiscal year outlook, lowering sales growth expectations from 13%-21% to 8%-14% and operating profit growth from 16%-24% to 10%-16%. The primary reasons for this adjustment are the slower growth of core products Wegovy and Ozempic, with demand for Wegovy in the U.S. obesity market falling short of expectations [6]. Financial Performance - Despite the guidance being lowered, Novo Nordisk's quarterly performance remains robust, with net sales for the first half of 2025 reaching 154.944 billion Danish Krone, a 16.1% year-over-year increase. Operating profit was 72.240 billion Danish Krone, up 25.0%, and diluted earnings per share increased by 22.8% to 12.49 Danish Krone [7]. Long-term Investment Perspective - The decline in stock price has brought Novo Nordisk's valuation back to an attractive range. While short-term performance may be under pressure, the strength of core products, global expansion potential, and patent barriers remain solid. As capital expenditures transition into production capacity, long-term profitability is expected to improve, making it a noteworthy consideration for long-term investors [2][7].

Core Viewpoint - The article highlights the rapid growth of online pharmacy sales in China, particularly focusing on the significant rise of GLP-1 receptor agonists like Semaglutide, which is becoming a leading treatment for obesity and diabetes management [5][6][9]. Group 1: Online Pharmacy Sales Growth - In 2024, online pharmacy sales in China are projected to exceed 70 billion yuan, with a remarkable year-on-year growth of 80.79% in the first quarter of 2025 [5]. - The top-selling drug in online pharmacies is Novo Nordisk's Semaglutide injection, achieving sales of 1.776 billion yuan, a staggering increase of 142% year-on-year [6]. Group 2: Market Composition and Trends - The digestive system and metabolic drugs account for the highest sales at 24.72%, followed by dermatological drugs (12.2%), reproductive and urinary system drugs (10.76%), and cardiovascular drugs (10%) [8]. - Oral formulations dominate the market with a share of 76.97%, indicating a strong preference for this delivery method among consumers [8]. Group 3: Demand for GLP-1 Receptor Agonists - The demand for GLP-1 receptor agonists is expected to surge due to the rising prevalence of obesity and type 2 diabetes, with the World Health Organization reporting a more than doubling of adult obesity rates since 1990 [9][10]. - By 2033, it is projected that GLP-1 drugs will generate sales of 168 billion USD across 68 pharmaceutical markets, with North America accounting for 68% of this figure [10].

Group 1 - Ukrainian President Zelensky arrived in Washington for a meeting with President Trump, scheduled for August 18, 1:15 PM ET, followed by a multilateral meeting with European leaders to discuss the Russia-Ukraine conflict [1] - Major U.S. stock index futures showed a decline, with Dow futures down 0.15%, S&P 500 futures down 0.16%, and Nasdaq futures down 0.16% [2] - U.S. semiconductor stocks experienced a collective drop, with Intel down 1.18%, AMD down 0.77%, and Nvidia down 0.38% [3] Group 2 - The Federal Reserve announced the cessation of its "new activity regulatory program" aimed at enhancing cryptocurrency business oversight in banks, leading to declines in cryptocurrency exchange stocks, with Coinbase down 1.67% and Circle down 1.07% [5] - Novo Nordisk's weight loss drug Wegovy received FDA approval for treating metabolic fatty liver disease, resulting in a 4.02% increase in the company's stock [6] - OpenAI employees plan to sell approximately $6 billion worth of stock at a valuation of $500 billion to a group of investors including Thrive Capital and SoftBank [7] Group 3 - Tesla is offering rental discounts of about 40% in the UK due to a significant drop in sales, with July sales falling to 987 units, a year-on-year decrease of approximately 60% [8] - NIO announced plans to enter the markets of Singapore, Uzbekistan, and Costa Rica between 2025 and 2026, with a collaboration in Singapore to launch its first right-hand drive model [9]